Patient Convenience Study

Boehringer Ingelheim1,852 enrolled

Overview

The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).

Study Type

OBSERVATIONAL

Enrollment

1,852

Conditions

Atrial Fibrillation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: Cohort A: 1. A. Written informed consent prior to participation 2. A. Female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation. 3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment. 4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion. OR Cohort B: 1. B. Written informed consent prior to participation. 2. B. Female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment). 3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion. Exclusion criteria: 1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC). 2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation. 3. Current participation in any clinical trial of a drug or device. 4. Current participation in an European registry on the use of oral anticoagulation in AF.

Locations (148)

Outcomes

Primary Outcomes

Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment

The PACT-Q is a self-administered questionnaire which was developed as a means to investigate patients´ satisfaction with anticoagulant treatment and treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 is composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score (CDS). Items for anticoagulant treatment satisfaction are summed and rescaled on a 0-100 scale to determine the satisfaction dimension score (SDS). High scores are more favorable. The two dimension scores are presented for Baseline, Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).

Time frame: Baseline, Visit 2 (7-124 days after initiation on Pradaxa® or VKA), Visit 3 (125-365 days after initiation on Pradaxa® or VKA).

Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups

The PACT-Q2 is composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction are summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores are more favorable. The two dimension scores are presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD). Propensity score matching method is used to identify matched Pradaxa® and VKA patients. Only the matched patients in each treatment group are summarized and used for comparison.

Time frame: Visit 2 (7-124 days after initiation on Pradaxa® or VKA) and Visit 3 (125-365 days after initiation on Pradaxa® or VKA).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

1160.247.1019 Boehringer Ingelheim Investigational Site

Braine-l'Alleud, Belgium

1160.247.1001 Boehringer Ingelheim Investigational Site

Brussels, Belgium

1160.247.1018 Boehringer Ingelheim Investigational Site

Brussels, Belgium

1160.247.1020 Boehringer Ingelheim Investigational Site

Brussels, Belgium

1160.247.1013 Boehringer Ingelheim Investigational Site

De Pinte, Belgium

1160.247.1010 Boehringer Ingelheim Investigational Site

Dendermonde, Belgium

1160.247.1011 Boehringer Ingelheim Investigational Site

Diest, Belgium

1160.247.1014 Boehringer Ingelheim Investigational Site

Edegem, Belgium

1160.247.1007 Boehringer Ingelheim Investigational Site

Leuven, Belgium

1160.247.1021 Boehringer Ingelheim Investigational Site

Lier, Belgium

...and 138 more locations

Patient Characteristics at Baseline - CHA2DS2-VASc Stroke Risk Score and HAS-BLED Bleeding Risk Score

CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category. HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and Hypertension, Abnormal renal and liver function, Stroke (1 point), Bleeding history or predisposition, Labile INR, Elderly (\>65 years), Drugs and Alcohol. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome. HAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome. CHA2DS2-VASc stroke risk score and HAS-BLED bleeding risk score at baseline are patient characteristics.

Time frame: Baseline

Secondary Outcomes

Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment

Time frame: Visit 2 (7-124 days after initiation on Pradaxa® or VKA) and Visit 3 (125-365 days after initiation on Pradaxa® or VKA).

Description of PACT-Q1 Items for Patients in Cohort B at Baseline

The PACT-Q1 is composed of a single dimension (7 items), covering the expectations of patients regarding their anticoagulant treatment, and was to be administered before treatment initiation. The 7 items are: A1: How confident are you that your anticoagulant treatment will prevent blood clots? A2: Do you expect that your anticoagulant treatment will relieve some of the symptoms you experience? A3: Do you expect that your anticoagulant treatment will cause side effects such as minor bruises or bleeding? A4: How important is it for you to have an anticoagulant treatment that is easy to take? A5: How concerned are you about making mistakes when taking your anticoagulant treatment? A6: How important is it for you to take care of your anticoagulant treatment by yourself? A7: How concerned are you about how much you pay for your anticoagulant treatment? Responses ranged from 1 (Not at all) to 5 (Extremely/ Completely/ Very much).

Time frame: Baseline